AGM
NMRA icon

Alpine Global Management’s Neumora Therapeutics NMRA Stock Holding History

Alpine Global Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-65,728
Closed -$646K – 354
2024
Q2 		$646K Buy
+65,728
New +$680K 0.11% 153

Other funds holding NMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Alpine Global Management's NMRA Position: Q3 2024 in Review

Alpine Global Management sold out of Neumora Therapeutics (NMRA) in Q3 2024, closing a stake of 65,728 shares — an estimated $646K sold.

Alpine Global Management first reported a position in NMRA in Q2 2024 and held it in 1 quarter. The position peaked at $646K in Q2 2024. 104 funds tracked by Wall St. Rank hold NMRA as of Q3 2024.

  • Alpine Global Management reported no remaining Neumora Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 65,728 Neumora Therapeutics shares in Q3 2024, an estimated $646K.
  • Alpine Global Management first reported a position in Neumora Therapeutics in Q2 2024 and held it in 1 quarter.
  • Alpine Global Management's Neumora Therapeutics position peaked at $646K in Q2 2024.
  • 104 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.